Belzutifan plus lenvatinib show promise as a second-line treatment for advanced kidney cancer
A recent study, called the Phase 3 LITESPARK-011 trial, looked [...]
Pembrolizumab plus belzutifan combination shows promise as an adjuvant treatment for kidney cancer
A large phase 3 clinical trial tested two medicines, pembrolizumab [...]
Bevacizumab plus erlotinib shows antitumor activity in advanced papillary kidney cancer
A recent phase 2 study, published in the New England [...]
Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
First-line benmelstobart plus anlotinib versus sunitinib in advanced kidney cancer
A new immunotherapy called benmelstobart, which blocks the action of [...]
Combination treatment shows benefits in rare, aggressive kidney cancer
Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare [...]
Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Pembrolizumab plus axitinib shows sustained benefit in advanced kidney cancer
The final long-term follow-up data from the phase 3 KEYNOTE-426 [...]
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line treatment for metastatic kidney cancer
Treatment of advanced (metastatic) kidney cancer has improved considerably over [...]
Immunotherapy for the treatment of non-clear cell kidney cancer
There are several types of kidney cancer, the most common [...]
